EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Ubiquitination in hepatocellular carcinoma: mechanisms and therapeutic opportunities

Xiaonan Geng, Bing Feng, Xufeng Huang, Wei Wang, Xinjun Hu

Protein & Peptide Letters · 2026-08 · 34 (1) · 1-4

DOI: 10.1016/j.ppl.2026.07.003 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Protein & Peptide Letters, 2026-08. Verfasst von Xiaonan Geng und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Infectious Diseases, The First Affiliated Hospital, College of Clinical Medicine, Henan University of Science and Technology, Luoyang, …. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 9 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Hepatocellular carcinoma (HCC) is the most prevalent form of primary liver cancer, characterized by high malignancy and insidious onset. The majority of patients are diagnosed at intermediate or advanced stages, thereby missing the optimal window for curative treatment. Currently, the combination of targeted agents and immune checkpoint inhibitors (ICIs) represents the standard first-line therapeutic. Nevertheless, the progressive emergence of drug tolerance has become a major clinical concern, highlighting the urgent need for novel targeted therapeutics. Accumulating evidence indicates that dysregulation of the ubiquitination machinery and deubiquitinating enzymes represents a hallmark feature across multiple cancer types. In HCC, the UPS not only orchestrates the degradation of substrate proteins but also modulates the metabolic reprogramming, immune evasion and therapeutic resistance, thereby promoting the proliferation, invasion, and metastasis of HCC cells.This work systematically delineates the roles and molecular mechanisms of ubiquitination in HCC, evaluates its therapeutic potential, and aims to provide a theoretical foundation and critical insights for the development of novel and effective treatment strategies against HCC.

Schlagwörter

Stichwörter der Autor:innen

Hepatocellular carcinomaOncotherapyUbiquitination

Autor:innen und Institutionen

  • Department of Infectious Diseases, The First Affiliated Hospital, College of Clinical Medicine, Henan University of Science and Technology, Luoyang, Henan, 471000, China.
  • Department of Hepatobiliary and Pancreatic Surgery, The First Affiliated Hospital, College of Clinical Medicine, Henan University of Science and Technology, Luoyang, Henan, 471000, China.
  • Department of Data Visualization, Faculty of Informatics, University of Debrecen, Debrecen, Hungary.
  • Department of Hepatobiliary and Pancreatic Surgery, The First Affiliated Hospital, College of Clinical Medicine, Henan University of Science and Technology, Luoyang, Henan, 471000, China. Electronic address: 13937928345…
  • Department of Infectious Diseases, The First Affiliated Hospital, College of Clinical Medicine, Henan University of Science and Technology, Luoyang, Henan, 471000, China. Electronic address: hxj5129@163.com.

Zitieren

APA

Geng, X., Feng, B., Huang, X., Wang, W., & Hu, X. (2026). Ubiquitination in hepatocellular carcinoma: mechanisms and therapeutic opportunities. Protein & Peptide Letters, 34(1), 1-4. https://doi.org/10.1016/j.ppl.2026.07.003

Vancouver

Geng X, Feng B, Huang X, Wang W, Hu X. Ubiquitination in hepatocellular carcinoma: mechanisms and therapeutic opportunities. Protein & Peptide Letters. 2026;34(1):1-4. doi:10.1016/j.ppl.2026.07.003

BibTeX
@article{Geng2026,
  author = {Geng, Xiaonan and Feng, Bing and Huang, Xufeng and Wang, Wei and Hu, Xinjun},
  title = {Ubiquitination in hepatocellular carcinoma: mechanisms and therapeutic opportunities},
  journal = {Protein & Peptide Letters},
  year = {2026},
  volume = {34},
  number = {1},
  pages = {1--4},
  doi = {10.1016/j.ppl.2026.07.003}
}
Kostenlos starten →